Recent studies have shown that RECQL4 overexpression occurs in prostate cancer, sporadic osteosarcoma, sporadic breast cancer, colorectal cancer, liver cancer, and gastric cancer, and is significantly associated with clinical outcomes19–23. Here, RECQL4 is linked to prostate carcinoma.